Lupin Limited, well-established pharmaceutical company, has announced that its Japanese subsidiary, Kyowa Pharmaceutical Industry Co Ltd, (Kyowa) has received approvals for 10 products from the Ministry of Health & Labour Welfare, Japan (MHLW).

Kyowa’s expanded product basket will now include ten more products and these are Amlodipine (CVS), Risperidone (line extension; CNS), Cabergoline (CNS), Milnacipran (CNS), Tandospirone (CNS), Meloxicam (NSAID), Fluticasone (line extension for pediatrics; Anti-Asthma), Quazepam (line extension; CNS), Ethyl Icosapentate (line extension) and Maprotiline (line extension; CNS). The combined market size of these molecules in Japan is JPY 265 Bn (USD 2.65 billion) as per IMS 2007.

The company said that it expects to launch these products by July 2008.

Lupin had acquired Kyowa in October 2007 and it is currently focusing on enriching its product basket and expanding its therapy width. These fresh approvals will strengthen Lupin’s position in the worlds’ second largest pharmaceutical market.